Moberg Pharma: Completion of recruitment confirms the time plan
Research Note
2019-03-22
09:45
The recruitment of patients into the ongoing European Phase 3 trial with MOB-015 has been completed. Topline results from the trial are expected in Q2 2020, which are in-line with our expectations, why we reiterate our base case fair value of SEK 87.
KP
Klas Palin
Disclosures and disclaimers